Shilpa Medicare Ltd share price logo

Shilpa Medicare Ltd Share Price

(SHILPAMED)

Small Cap

Healthcare Sector

₹664.45▲1.96%

as on 04:01PM, 29 Apr 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Shilpa Medicare Performance

  • Day's Low

    Day's High

    ₹661.5
    Day's Price Range
    ₹685.75

  • 52 Week's Low

    52 Week's High

    ₹417.6
    52-Week Price Range
    ₹959.5
1 Month Return+ 1.09 %
3 Month Return-5.79 %
1 Year Return+ 20.73 %
Previous Close₹677.75
Open₹676.05
Volume65.92K
Upper Circuit₹813.30
Lower Circuit₹542.20
Market Cap₹6,497.72Cr

Shilpa Medicare Fundamentals

P/E Ratio

70.99

PEG Ratio

7.53

Market Cap

₹6,497.72 Cr

P/B Ratio

1.87

EPS

3.68

Dividend Yield

0

Sector

Pharmaceuticals

ROE

1.59

Shilpa Medicare Analyst Rating

based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts offering long term price targets for Shilpa Medicare. An average target of ₹1191

Source: S&P Global Market Intelligence

Shilpa Medicare Share analysis

Shilpa Medicare price forecast by 2 analysts

Upside of79.25%

High

₹1525

Target

₹1191.00

Low

₹857

Shilpa Medicare target price ₹1191, a slight upside of 79.25% compared to current price of ₹664.45. According to 2 analysts rating.

Source: S&P Global Market Intelligence

Key events for Shilpa Medicare Ltd

  • Shilpa Medicare Settles Arbitration with Celltrion - 17 Apr, 2025

    Shilpa Medicare has settled its arbitration dispute with Celltrion for $3.4 million, resolving a previous award of approximately $3.7 million. The settlement will be paid in installments by July 2025 and will not affect future operations.

  • Shilpa Medicare Secures USFDA Approval for Varenicline - 09 Apr, 2025

    Shilpa Medicare has received USFDA approval for its Varenicline tablets, a generic version of Chantix, targeting the $203 million U.S. smoking cessation market. This approval enhances Shilpa's position in the pharmaceutical sector.

  • Shilpa Medicare Launches BORUZU Injections in US Market - 03 Apr, 2025

    Shilpa Medicare's marketing partner, Amneal Pharmaceuticals, launched BORUZU injections in the US, boosting Shilpa's stock by 4.73%. This ready-to-use oncology product enhances patient compliance and reduces preparation time. The company also reported significant profit growth in Q3 FY25.

  • Shilpa Medicare Launches Novel Injectable Product - 01 Apr, 2025

    Shilpa Medicare has developed a new molecule, with Amneal set to manufacture and commercialize it in the US. This launch reflects Shilpa's commitment to innovative pharmaceutical solutions that enhance patient compliance and reduce wait times.

Insights on Shilpa Medicare Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, SHILPAMED stock has moved up by 26.3%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, 14.06 Cr → 31.78 Cr (in ₹), with an average increase of 32.6% per quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 9.90% to 10.97% in Mar 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 51.1% return, outperforming this stock by 24.7%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 44.23% of holdings in Mar 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.0% return, outperforming this stock by 88.5%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 37.60% to 37.25% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 4.89% to 4.05% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 348.79 Cr → 320.79 Cr (in ₹), with an average decrease of 8.0% per quarter

Shilpa Medicare Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹286.76Cr (-)₹291.69Cr (↑1.72%)₹292.51Cr (↑0.28%)₹343.80Cr (↑17.53%)₹319.32Cr (↓7.12%)
Net Income₹4.70Cr (-)₹24.50Cr (↑421.28%)₹14.06Cr (↓42.61%)₹17.94Cr (↑27.60%)₹31.78Cr (↑77.15%)
Net Profit Margin1.64% (-)8.40% (↑412.20%)4.81% (↓42.74%)5.22% (↑8.52%)9.95% (↑90.61%)
Value in ₹ crore
Details2021202220232024
Total Assets₹2,554.73Cr (-)₹2,966.00Cr (↑16.10%)₹2,597.16Cr (↓12.44%)₹2,501.48Cr (↓3.68%)
Total Liabilities₹916.90Cr (-)₹900.33Cr (↓1.81%)₹479.58Cr (↓46.73%)₹358.76Cr (↓25.19%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹129.79Cr (-)₹69.63Cr (↓46.35%)₹173.87Cr (↑149.71%)₹2.08Cr (↓98.80%)₹8.03Cr (↑286.06%)

Shilpa Medicare Index Inclusions

BSE Healthcare

₹42,211.90

-0.81 (▲-343.75%)

BSE Small-Cap

₹48,238.69

0.09 (▲45.23%)

Shilpa Medicare Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
44.23%
0.00
Foreign Institutions
10.97%
0.00
Mutual Funds
4.05%
0.00
Retail Investors
37.25%
0.00
Others
3.5%
0.00

Shilpa Medicare Key Indicators

Details20202021202220232024
Return On Assets %7.555.782.05-1.251.27
Details20202021202220232024
Book Value Per Share (₹)163.06181.37209.93205.44208.37
Details20202021202220232024
Earning Per Share (₹)18.9617.936.98-3.573.68
Details20202021202220232024
Return On Equity %14.178.937.173.491.59

Shilpa Medicare Valuation

Shilpa Medicare in the last 5 years

  • Overview

  • Trends

Lowest (-6579.29x)

March 28, 2024

Industry (54.77x)

April 29, 2025

Today (70.99x)

April 29, 2025

Highest (503.73x)

February 21, 2023

LowHigh

Shilpa Medicare Earnings and Dividends

  • Shilpa Medicare Ltd Earnings Results

    Shilpa Medicare Ltd’s net profit jumped 593.89% since last year same period to ₹31.78Cr in the Q3 2024-2025. On a quarterly growth basis, Shilpa Medicare Ltd has generated 77.15% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Shilpa Medicare Ltd Dividends May,2022

    In the quarter ending March 2022, Shilpa Medicare Ltd has declared dividend of ₹1.10 - translating a dividend yield of 0.33%.

    Read More about Dividends

Shilpa Medicare Technicals Summary

Bearish

Neutral

Bullish

Bearish

Shilpa Medicare Ltd is currently in a Bearish trading position according to technical analysis indicators.

More on Technical Analysis

Shilpa Medicare Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Shilpa Medicare Ltd
Shilpa Medicare Ltd
BUY₹6,497.72 Cr16.51%0.53₹31 Cr₹1,151 Cr
Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Ltd
BUY₹28,928.76 Cr133.26%0.52₹300 Cr₹1,051 Cr
Jubilant Pharmova Ltd
Jubilant Pharmova Ltd
BUY₹14,252.57 Cr31.52%0.57₹72 Cr₹6,702 Cr
Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Ltd
NA₹4,817.52 Cr2.55%0.79-₹388 Cr₹75 Cr
Rainbow Childrens Medicare Ltd
Rainbow Childrens Medicare Ltd
BUY₹13,783.61 Cr40.3%0.68₹218 Cr₹1,296 Cr
See all

About Shilpa Medicare

Shilpa Medicare Limited (SML) was established in 1987 and converted to a public limited company in 1993. They are one of the leading API and formulations manufacturers, with expertise in oncology and non-oncology medicines, with over 44 APIs and 16 injectable dosage forms and 19 oral solid dosage forms. SML deploy sophisticated technology in order to comply with international standards. In 2015, funds were raised by allotting 1.76 Mn equity shares at Rs. 423/ share, and in 2016, the face value of equity shares was split into two equity shares of Rs.1/ each. Raichem Medicare Pvt. Ltd., a subsidiary of SML successfully installed all machinery and recruited personnel. During FY16, they launched generic versions of Vidaza Injection and Xeloda Tablets. In 2017, Navya Biologicals Private Limited was acquired and in 2019, they invested Rs 22.71 cr in Shilpa Therapeutics Pvt. Ltd and disinvested 24% stake in Raichem Medicare Pvt. Ltd. In 2021, they launched a pediatric dose paracetamol oral thin film, Molshil and acquired stake in FTF Pharma Pvt. Ltd, Koanaa Healthcare Canada, etc. In 2022, they approved Slump sale of Active Pharmaceutical Ingredient API Business to Shilpa Pharma Lifesciences Limited.

Revenue: ₹319.32Cr as on December 2024 (Q4 24)
Net Profit: ₹31.78Cr as on December 2024 (Q4 24)
Listing date: 03 Dec, 2009
Chairperson Name: Omprakash Inani
OrganisationShilpa Medicare
Headquarters
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Shilpa Medicare Ltd

What is Shilpa Medicare Ltd price today?

Shilpa Medicare Ltd share price today stands at ₹664.45, Open: ₹676.05, Previous Close: ₹677.75, High: ₹685.75, Low: ₹661.5, 52 Week High: ₹959.5, 52 Week Low: ₹417.6.

How to Buy Shilpa Medicare Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Shilpa Medicare Ltd shares

What are today's traded volumes of Shilpa Medicare Ltd?

Today's traded volume of Shilpa Medicare Ltd(SHILPAMED) is 65.92K.

What is today's market capitalisation of Shilpa Medicare Ltd?

Today's market capitalisation of Shilpa Medicare Ltd(SHILPAMED) is ₹6497.72Cr.

What is the 52 Week High and Low Range of Shilpa Medicare Ltd?

Shilpa Medicare Ltd (SHILPAMED)
Price
52 Week High
₹959.5
52 Week Low
₹417.6

How much percentage Shilpa Medicare Ltd is down from its 52 Week High?

Shilpa Medicare Ltd (SHILPAMED) share price is ₹664.45. It is down -30.75% from its 52 Week High price of ₹959.5

How much percentage Shilpa Medicare Ltd is up from its 52 Week low?

Shilpa Medicare Ltd (SHILPAMED) share price is ₹664.45. It is up 59.11% from its 52 Week Low price of ₹417.6